Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Retrospective Observational Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06806488

Acronym

MarZoLyOss

Enrollment

160

Registered

2025-02-04

Start date

2025-05-31

Completion date

2025-10-31

Last updated

2025-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Marginal Zone B Cell Lymphoma

Brief summary

This is a purely retrospective and observational monocentric study

Detailed description

the study aimed at describing the characteristics and outcome of Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018. 2. Age ≥ 18 years at enrolment. 3. Written informed consent (if applicable)

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
clinical characteristics of Marginal zone lymphoma patients	through study completion, an average of 1 years	to descrive clinical characteristics of Marginal zone lymphoma patients who were diagnosed and treated in our Hospital.

Secondary

Measure	Time frame	Description
effectiveness	through study completion, an average of 1 years	It includes: 1. Description of treatment duration and causes of treatment discontinuation. 2. Description of adverse events / safety of the treatments 3. Assessment of patients' survival. 4. Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions. 5. Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases
safety	through study completion, an average of 1 years	It includes: 1. Description of treatment duration and causes of treatment discontinuation. 2. Description of adverse events / safety of the treatments 3. Assessment of patients' survival. 4. Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions. 5. Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases

Countries

Italy

Contacts

Primary ContactPier Luigi Zinzani, MD

pierluigi.zinzani@unibo.it+39 0512143680

Backup ContactAlessandro Broccoli, MD

Alessandro.broccoli@studio.unibo.it+39 0512143680

Outcome results